India has recorded lower rates of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE) than the US and parts of Europe, even as recent data highlight a high prevalence of multidrug-resistant organisms (MDROs) among certain high-risk patients, official sources have said. Authorities stressed that these findings must be interpreted carefully and do not indicate a widespread treatment failure or uncontrolled antimicrobial resistance in the general population.
The clarification follows a Lancet-published international, multicentre cross-sectional study on patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) across tertiary care centres in the Netherlands, India, Italy and the USA, which found that 83.1% of Indian ERCP patients were colonised with at least one MDRO. Experts from the National Centre for Disease Control (NCDC) underlined that this cohort represents a high‑risk clinical group with multiple comorbidities, frequent healthcare exposure and higher antibiotic use, and therefore cannot be considered representative of the wider Indian population or routine healthcare settings.
Officials emphasised the critical distinction between colonisation and infection, noting that colonisation only indicates the presence of organisms and does not by itself mean clinical infection, treatment failure, or worse outcomes. They further pointed out that the study did not report higher ERCP-associated infection or mortality risk among Indian patients, reinforcing that high colonisation rates do not automatically translate into adverse clinical consequences.
Contrary to fears of a broad AMR crisis, the study data cited by officials show India has significantly lower MRSA prevalence at 1.4% and VRE prevalence at 7.4% compared to the US and parts of Europe, which they say reflects the effectiveness of current containment strategies for gram‑positive infections. NCDC experts, however, cautioned that microbial resistance patterns vary regionally and must be assessed in the context of factors such as population density, disease burden and healthcare access, with the study itself calling for region-specific prevention strategies.
Officials also warned against linking the ERCP colonisation findings directly to alleged excessive antibiotic use in India, explaining that cross-sectional studies cannot establish causation or measure community-level spread of MDR organisms. Reiterating the need for balance, NCDC experts said that while antimicrobial resistance remains a serious global concern, the current study should not be misrepresented as evidence of systemic failure, but rather as a reminder to strengthen surveillance, infection control and antimicrobial stewardship without fuelling unnecessary alarm.
